Fig. 3. TNF-α inhibits sGCβ1 expression through the biogenesis of NF-κB-responsive miR-155.

a HASMCs were treated with TNF-α (10 ng/mL), and the miR-155 levels were determined by qRT-PCR (n = 3). b–d HASMCs were transfected with 80 nM of control (C) or NF-κB p65 siRNA (N) and treated with or without TNF-α in the presence or absence of Bay11-7082 (Bay, 5 μM) for 24 h. b, c The miR-155 and sGCβ1 mRNA levels were determined by qRT-PCR (n = 6). d The sGCβ1 protein levels were determined by Western blotting (n = 3). *P < 0.05 and **P < 0.01